Abstract 789P
Background
Seventy percent of testicular non-seminomatous germ cell tumors (NSGCT) are cured with only orchiectomy, so the adjuvant treatment is an overtreatment in most patients. The objective of the study was to find a gene expression model that would help us select the patients with the highest risk of relapse.
Methods
Retrospective study of 54 patients with stage I NSGCT without adjuvant treatment (48% with relapse and 52% without relapse). Gene expression differences were analyzed using the PanCancer panel. Bioinformatics tools were used to find a gene expression signature, based on the selection of embedded type characteristics, using nine classification models (Lasso, Ridge, Gradient Boosting, Random Forest, ExtraTrees, LogisticRegression, SGDC, Passive Aggressive Classifier and SVR).
Results
A nine gene model (MPL, Col24a1, NR4A1, FOSL1, CREB5, FANCB, LAMB4, ZBTB16, CALML3) was obtained with the ability to predict the risk of relapse in patients with NSGCT stage I without adjuvant treatment, AUC 0.8. Of these genes, four are related to the PI3K signaling pathway (Col24a1, NR4A1, CREB5, LAMB4). From the nine gene model highlights FOSL1, with a correlation with relapse of 0.43, and NR4A1 and ZBTB16, with a differential expression close to statistical significance (0.075 in both cases).
Conclusions
In stage I NSGCT treated with only orchiectomy a differential gene expression signature of nine genes has been identified (MPL, Col24a1, NR4A1, FOSL1, CREB5, FANCB, LAMB4, ZBTB16, CALML3) that allows selecting those patients with a high risk of relapse, although these data need validation in a larger population of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.